PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I:
wherein R
1
, R
2
, R
3
, and R
4
are as defined herein.
Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses (Ia), wherein R
1
and R
2
are the same or different and represent hydrogen, halogen, -L-O—R
3
, -L-O-L-A or -L-O-L′-A′, wherein each L is the same or different and represents a direct bond or a C
1
-C
4
alkylene group; L′ represents a direct bond or a C
2
-C
4
alkylene group; R
3
represents hydrogen, C
1
-C
4
alkyl or C
1
-C
4
haloalkyl; A represents a 5- to 10-membered heterocyclyl group; and A′ represents a C
6
-C
1
aryl group; wherein at least one of R
1
and R
2
is -L-O—R
3
, -L-O-L-A or -L-O-L′-A′.
Starting from natural product podophyllotoxin 1 substituted heterolignans were identified with promising insecticidal in vivo activity. The impact of substitution in each segment of the core structure was investigated in a detailed SAR study, and variation of substituents in both aromatic moieties afforded derivatives 5 and 43 with broad insecticidal activity against lepidopteran and coleopteran species. In vitro measurements supported by modeling studies indicate that heterolignans 3-134 act as tubuline polymerization inhibitors interacting with the colchicine-binding site. Insect specific structure-activity effects were observed showing that the insecticidal SAR described herein differs from reported cytotoxicity studies. (C) 2009 Elsevier Ltd. All rights reserved.
KODZIMA, KADZUXIRO;ITO, XARUAKI
作者:KODZIMA, KADZUXIRO、ITO, XARUAKI
DOI:——
日期:——
HETEROBICYCLIC METALLOPROTEASE INHIBITORS
申请人:Steeneck Christoph
公开号:US20120015920A1
公开(公告)日:2012-01-19
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.